| Literature DB >> 36267656 |
Hui Lei1, Shunmei Zou1, Jiafu Lin2, Longfei Zhai3, Yifeng Zhang1, Xiujuan Fu1, Siwei Chen1, Hong Niu1, Feifei Liu4, Chunlian Wu5, Dan Zhang1.
Abstract
Dendrobium nobile (Lindl.) have long been used as herbal tea and a traditional herbal medicine to treat Alzheimer's disease (AD). In the current study, nineteen compounds (1-19), including two new vitamin E homologues (1-2), one new sesquiterpene (6), and two new dendrobines (7, 8), were isolated and identified from stems of Dendrobium nobile. Their structures were elucidated on the basis of NMR, 13C NMR calculation, and DP4+ probability analyses. The absolute configurations of new compounds were determined by electronic circular dichroism (ECD) data analysis. Antioxidant, anti-inflammatory, and cytotoxic activities of isolated compounds were evaluated. Among them, compound 2 demonstrated significant antioxidant activity compared with ascorbic acid (VC), while compounds 2 and 4 also exhibited an equal effect to positive control cisplatin. This study on the biological activity of the new vitamin E homologues from Dendrobium nobile may indicate its potential application in the pharmaceutical and food industries.Entities:
Keywords: Dendrobium nobile Lindl.; anti-inflammatory activities; antioxidant; chemical constituents; structure-activity relationship
Year: 2022 PMID: 36267656 PMCID: PMC9577000 DOI: 10.3389/fchem.2022.988459
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
FIGURE 1Structures of compounds 1–19.
1H and13C NMR (600 MHz) data for 1 and 2 in CDCl3.
| No. | 1 | 2 | ||
|---|---|---|---|---|
| δC, type | δH (J in Hz) | δC, type | δH (J in Hz) | |
| 1 | — | — | — | — |
| 2 | 74.5, C | — | 75.2, C | — |
| 3 | 31.6, CH2 | 1.78, m | 30.8, CH2 | 1.82, m |
| 4 | 20.8, CH2 | 2.60, t (6.9) | 18.4, CH2 | 3.03, t (6.8) |
| 5 | 118.6, C | — | 124.2, C | — |
| 6 | 144.5, C | — | 155.8, C | — |
| 7 | 121.1, C | — | 114.5, C | — |
| 8 | 122.6, C | — | 138.4, C | — |
| 9 | 145.5, C | — | 144.0, C | — |
| 10 | 117.4, C | — | 117.6, C | — |
| 1′ | 39.7, CH2 | 1.53, m | 39.5, CH2 | 1.55, m |
| 2′ | 21.0, CH2 | 1.39, m | 20.9, CH2 | 1.40, m |
| 3′ | 37.6, CH2 | 1.27, m | 37.6, CH2 | 1.26, m |
| 4′ | 32.8, CH | 1.39, m | 32.8, CH | 1.39, m |
| 5′ | 37.5, CH2 | 1.27, m | 37.4, CH2 | 1.26, m |
| 6′ | 24.5, CH2 | 1.06, m | 24.5, CH2 | 1.06, m |
| 7′ | 37.4, CH2 | 1.07, m | 37.4, CH2 | 1.08, m |
| 8′ | 32.7, CH | 1.39, m | 32.7, CH | 1.39, m |
| 9′ | 37.4, CH2 | 1.07, m | 37.4, CH2 | 1.08, m |
| 10′ | 21.8, CH2 | 1.30, m | 21.8, CH2 | 1.30, m |
| 11′ | 44.3, CH2 | 1.43, m | 44.3, CH2 | 1.43, m |
| 12′ | 71.2, C | — | 71.1, C | — |
| 13′ | 29.3, CH3 | 1.25, m | 29.7, CH3 | 1.25, m |
| Me-2a | 23.8, CH3 | 1.23, m | 23.7, CH3 | 1.23, s |
| Me-5a | 11.3, CH3 | 2.11, s | 11.3, CH3 | 2.15, s |
| Me-7a | 12.3, CH3 | 2.16, s | 194.0, C | 10.20, s |
| Me-8a | 11.8, CH3 | 2.14, s | 13.2, CH3 | 2.17, s |
| Me-4′a | 19.7, CH3 | 0.85, d (6.6) | 19.7, CH3 | 0.85, d (6.6) |
| Me-8′a | 19.7, CH3 | 0.86, d (6.6) | 19.7, CH3 | 0.86, d (6.3) |
| Me-12′a | 29.2, CH3 | 1.18, m | 29.3, CH3 | 1.26, m |
1H and13C NMR (600 MHz) data for 6-8 in CDCl3.
| NO. | 6 | 7 | 8 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 68.9, CH | 4.13, d (4.8) | 54.5, C | — | 49.4, C | — |
| 2 | 122.0, CH | 5.38, d (6.0) | 68.7, CH | 2.90, s | 50.5, CH | 4.49, d (10.3) |
| 3 | 128.7, C | — | 79.1, CH | 4.93, m | 82.1, CH | 4.44, d (4.5) |
| 4 | 37.4, CH2 | 2.59, m, 1.96, m | 51.2, CH | 2.17, m | 53.0, CH | 2.18, m |
| 5 | 46.8, CH | 1.93, m | 43.5, CH | 2.25, m, 2.19, m | 48.1, CH | 3.01, d (4.3) |
| 6 | 49.7, CH | 2.47, dd (12.0, 3.6) | 43.7, CH | 2.51, m, 2.44, m | 77.6, C | — |
| 7 | 32.2, CH2 | 1.45, m | 36.0, CH2 | 2.20, m, 1.90, m | 56.2, CH2 | 3.58, m |
| 8 | 32.0, CH2 | 1.71, m | 30.4, CH2 | 2.34, m | 64.0, CH | 3.71, m |
| 9 | 42.6, CH | 1.75, m | 104.8, C | — | 79.3, CH | 4.85, s |
| 10 | 72.0, C | — | 25.7, CH3 | 1.35, s | 170.1, C | — |
| 11 | 148.4, C | — | 69.5, CH | 3.57, d (6.0) | 24.9, CH3 | 1.29, s |
| 12 | 19.1, CH3 | 1.71, s | 178.8, C | — | 174.8, C | — |
| 13 | 111.0, CH2 | 4.75, d (12.0) | 24.9, CH | 1.81, m | 26.6, CH | 2.20, m |
| 14 | 15.2, CH3 | 1.12, d (6.5) | 20.5, CH3 | 0.99, s | 21.8, CH3 | 1.08, d (5.6) |
| 15 | 23.8, CH3 | 1.72, s | 21.2, CH3 | 0.98, s | 20.5, CH3 | 1.01, d (6.0) |
| 16 | — | — | 35.6, CH3 | 2.57, m | 161.3, CH | 8.25, s |
| 17 | — | — | — | — | 21.4, CH3 | 2.24, s |
| 1′ | — | — | 33.4, CH2 | 2.43, s | — | — |
| 2′ | — | — | 175.9, C | — | — | — |
FIGURE 2COSY and key HMBC correlations of 1–2, 6-8.
FIGURE 3Key NOESY correlations of compounds 1–2, 6-8.
FIGURE 4Linear regression fitting of computed 13C-NMR chemical shifts of the calculated configuration of compound 1 with the experimental values.
FIGURE 5CD spectrums of 1 and 2.
FIGURE 6Linear regression fitting of computed 13C-NMR chemical shifts of the calculated configuration of compound 6 with the experimental values.
FIGURE 7Comparison between calculated and experimental ECD spectra of 7 and 8.
SCHEME 1Plausible biosynthetic pathway of compounds 7 and 8.
DPPH free-radical-scavenging of compounds 1-19 .
| Sample | DPPH inhibition rate (%) | IC50 (μmol/L) |
|---|---|---|
|
| 43.21 | — |
|
| 90.02 | 59.13 ± 2 |
|
| 15.88 | — |
|
| 18.82 | — |
|
| 4.19 | — |
|
| 10.34 | — |
|
| 18.62 | — |
|
| 8.84 | — |
|
| 6.22 | — |
|
| 36.17 | — |
|
| 2.78 | — |
|
| 2.45 | — |
|
| 2.45 | — |
|
| 2.45 | — |
|
| 80.36 | 363.77 ± 3 |
| Ascorbic acid | 90.69 | 101.67 ± 0.2 |
Compounds that are not shown in this table did not exhibit activity.
Inhibition of NO production with IC50 values of compounds 17 and 19 .
| Sample | IC50 (μmol/L) |
|---|---|
|
| 36.70 ± 2 |
|
| 19.47 ± 1 |
| Dexamethasone | 17.46 ± 2 |
Compounds that are not shown in this table did not exhibit activity.
Cytotoxic (IC50 in μM) Activities of Compounds 1–4 .
| Sample | IC50 (HepG2)/μM | IC50 (Hela)/μM |
|---|---|---|
|
| >100 | — |
|
| 51.28 ± 3 | 18.71 ± 3 |
|
| 19.75 ± 1 | — |
|
| 37.06 ± 2 | 19.51 ± 1 |
| Cisplatin | 6.58 ± 3 | 14.93 ± 1 |
Compounds that are not shown in this table did not exhibit activity.